Combination therapy
Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a PD-1 or PD-L1 inhibitor to a patient.
1. A method for treating cancer, comprising administering:
(i) an effective amount of Compound I:
or a pharmaceutically acceptable salt thereof, and
(ii) an effective amount of a PD-1 inhibitor or PD-L1 inhibitor.
2. The method of claim 1 , wherein the PD-1 inhibitor or PD-L1 inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDR001, REGN2810, or durvalumab, or a variant or biosimilar thereof, or combinations thereof.
3. The method of claim 1 , wherein (ii) is an effective amount of a PD-1 inhibitor.
4. The method of claim 1 , wherein (ii) is an effective amount of a PD-L1 inhibitor.
5. The method of claim 3 , wherein the PD-1 inhibitor is pembrolizumab, or a variant or biosimilar thereof.
6. The method of claim 3 , wherein the PD-1 inhibitor is pembrolizumab.
7. The method of claim 1 , wherein the cancer is a hematological malignancy.
8. The method of claim 1 , wherein the cancer is a relapsed or refractory hematological malignancy.
9. The method of claim 1 , wherein the cancer is a B cell malignancy.
10. The method of claim 1 , wherein the cancer is a non-Hodgkin's lymphoma.
11. The method of claim 1 , wherein the cancer is chronic lymphocytic leukemia.
12. The method of claim 1 , wherein the cancer is follicular lymphoma.
13. The method of claim 1 , wherein the cancer is mantle cell lymphoma.
14. The method of claim 1 , wherein the cancer is extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, or splenic marginal zone lymphoma.
15. The method of claim 1 , wherein the cancer is non-small cell lung cancer.